These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 17578539)

  • 1. Dihydroergotamine for early and late treatment of migraine with cutaneous allodynia: an open-label pilot trial.
    Silberstein SD; Young WB; Hopkins MM; Gebeline-Myers C; Bradley KC
    Headache; 2007 Jun; 47(6):878-85. PubMed ID: 17578539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clarification of developing and established clinical allodynia and pain-free outcomes.
    Landy SH; McGinnis JE; McDonald SA
    Headache; 2007 Feb; 47(2):247-52. PubMed ID: 17300364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia.
    Burstein R; Collins B; Jakubowski M
    Ann Neurol; 2004 Jan; 55(1):19-26. PubMed ID: 14705108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of MAP0004, orally inhaled DHE in treating migraines with and without allodynia.
    Tepper SJ; Kori SH; Borland SW; Wang MH; Hu B; Mathew NT; Silberstein SD
    Headache; 2012 Jan; 52(1):37-47. PubMed ID: 22106843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors.
    Jakubowski M; Levy D; Goor-Aryeh I; Collins B; Bajwa Z; Burstein R
    Headache; 2005; 45(7):850-61. PubMed ID: 15985101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine.
    Aurora SK; Rozen TD; Kori SH; Shrewsbury SB
    Headache; 2009 Jun; 49(6):826-37. PubMed ID: 19545249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Almotriptan and its combination with aceclofenac for migraine attacks: a study of efficacy and the influence of auto-evaluated brush allodynia.
    Schoenen J; De Klippel N; Giurgea S; Herroelen L; Jacquy J; Louis P; Monseu G; Vandenheede M;
    Cephalalgia; 2008 Oct; 28(10):1095-105. PubMed ID: 18644036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study).
    Mathew NT; Finlayson G; Smith TR; Cady RK; Adelman J; Mao L; Wright P; Greenberg SJ;
    Headache; 2007 Feb; 47(2):189-98. PubMed ID: 17300358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of greater occipital nerve block and trigger point injection on brush allodynia and pain in migraine.
    Ashkenazi A; Young WB
    Headache; 2005 Apr; 45(4):350-4. PubMed ID: 15836572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine.
    Aurora SK; Silberstein SD; Kori SH; Tepper SJ; Borland SW; Wang M; Dodick DW
    Headache; 2011 Apr; 51(4):507-17. PubMed ID: 21457235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sumatriptan-naproxen migraine efficacy in allodynic patients: early intervention.
    Landy S; Hoagland R; Hoagland NA
    Headache; 2012 Jan; 52(1):133-9. PubMed ID: 21883200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repetitive dihydroergotamine nasal spray for treatment of refractory headaches: an open-label pilot study.
    Weintraub J
    Curr Med Res Opin; 2006 Oct; 22(10):2031-6. PubMed ID: 17022862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis of menstrual headache and an open-label study among those with previously undiagnosed menstrually related migraine to evaluate the efficacy of sumatriptan 100 mg.
    Schreiber CP; Cady RK
    Clin Ther; 2007; 29 Suppl():2511-9. PubMed ID: 18164918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosing and administration of ergotamine tartrate and dihydroergotamine.
    Mathew NT
    Headache; 1997; 37 Suppl 1():S26-32. PubMed ID: 9009471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AXERT 12.5 mg Time Versus Intensity Migraine Study (AIMS).
    Freitag FG; Finlayson G; Rapoport AM; Elkind AH; Diamond ML; Unger JR; Fisher AC; Armstrong RB; Hulihan JF; Greenberg SJ;
    Headache; 2007 Apr; 47(4):519-30. PubMed ID: 17445101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, safety, and tolerability of dihydroergotamine nasal spray as monotherapy in the treatment of acute migraine. Dihydroergotamine Nasal Spray Multicenter Investigators.
    Headache; 1995 Apr; 35(4):177-84. PubMed ID: 7775172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous sumatriptan provides symptomatic relief at any pain intensity or time during the migraine attack.
    Linde M; Mellberg A; Dahlöf C
    Cephalalgia; 2006 Feb; 26(2):113-21. PubMed ID: 16426264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time to pain freedom and onset of pain relief with rizatriptan 10 mg and prescription usual-care oral medications in the acute treatment of migraine headaches: a multicenter, prospective, open-label, two-attack, crossover study.
    Bell CF; Foley KA; Barlas S; Solomon G; Hu XH
    Clin Ther; 2006 Jun; 28(6):872-80. PubMed ID: 16860170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R; Schreiber C
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous dihydroergotamine for inpatient management of refractory primary headaches.
    Nagy AJ; Gandhi S; Bhola R; Goadsby PJ
    Neurology; 2011 Nov; 77(20):1827-32. PubMed ID: 22049203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.